COVID-19 is an emerging, rapidly evolving situation.
ClinicalTrials.gov Identifier: NCT04536298
Brief Summary:
The Vitamin D and COVID-19 Trial (VIVID) is a nationwide randomized clinical trial in 2700 U.S. men and women to investigate whether taking a daily dietary supplement of vitamin D for 4 weeks reduces the risk of hospitalization and/or death in participants newly diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in their closest household contacts (as documented by seroconversion). Active Comparator: Vitamin D
Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28) A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members
Dietary Supplement: vitamin D
Vitamin D softgel capsules; each capsule contains
3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
- vitamin D3
- cholecalciferol
Sponsor:
Brigham and Women’s Hospital
Collaborators:
Harvard Medical School
Harvard School of Public Health
Harvard Pilgrim Healthcare Institute
Fenway Health and Beth Israel Deaconess Medical Center
Tishcon Corporation
Takeda
Quest Diagnostics
Karolinska Institutet
Philanthropic donations
Information provided by (Responsible Party):
JoAnn E. Manson, MD, Brigham and Women’s Hospital